表皮生长因子受体抑制剂治疗肺癌与角膜炎风险
这项基于美国TriNetX数据的队列研究纳入1 388 108例肺癌患者,其中22 225例接受表皮生长因子受体抑制剂(EGFRi)治疗;EGFRi治疗与角膜炎风险升高相关(HR 1.520;95% CI 1.339-1.725),其中阿法替尼风险较高(HR 2.229;95% CI 1.480-3.356)。
要点
- EGFRi治疗肺癌患者新发角膜炎风险高于未暴露患者(HR 1.520;95% CI 1.339-1.725)。
- 角膜炎亚型包括角结膜炎、浅层角膜炎和角膜溃疡,角膜溃疡HR 2.132(95% CI 1.515-3.002)。
- 阿法替尼与角膜炎风险升高相关(HR 2.229;95% CI 1.480-3.356)。
核心结论
- 研究提示接受EGFRi治疗的肺癌患者新发角膜炎风险可能升高,尤其是第二代EGFRi阿法替尼。
研究设计与样本
- 基于美国TriNetX数据的队列研究,纳入2003年5月1日至2023年10月30日期间接受或不接受EGFRi治疗的肺癌患者。
主要发现
- 在1 388 108例肺癌患者中,22 225例接受EGFRi治疗(平均[SD]年龄69.7[10.6]岁;女性62.8%,男性37.2%)。
- EGFRi治疗患者角膜炎风险高于未暴露患者(HR 1.520;95% CI 1.339-1.725)。
- EGFRi相关角膜炎亚型包括角结膜炎(HR 1.367;95% CI 1.158-1.615)、浅层角膜炎(HR 1.635;95% CI 1.306-2.047)和角膜溃疡(HR 2.132;95% CI 1.515-3.002)。
- 服用阿法替尼的患者角膜炎风险较高(HR 2.229;95% CI 1.480-3.356)。
临床怎么用
- 作者认为这些发现支持对EGFRi相关眼部问题进行及时诊断和管理,以预防严重并发症或治疗中断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epidermal growth factor receptor inhibitors (EGFRis) have been reported to be associated with cutaneous and ocular side effects; however, there is limited evidence of an association between EGFRi treatment and keratitis. OBJECTIVE: To determine the association between EGFRi treatment and agents and the risk of new-onset keratitis among patients with lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This US population-based cohort study examined TriNetX data of patients with lung cancer treated with or without EGFRis between May 1, 2003, and October 30, 2023. EXPOSURES: Treatment with EGFRis, including the first-generation agents gefitinib and erlotinib, the second-generation agent afatinib, and the third-generation agent osimertinib. MAIN OUTCOMES AND MEASURES: The risk of new-onset keratitis among patients with lung cancer receiving EGFRi treatment was determined using logistic and Cox proportional hazards regression. RESULTS: Among 1 388 108 patients with lung cancer, 22 225 received EGFRis (mean [SD] age, 69.7 [10.6] years; 62.8% females and 37.2% males). Patients treated with EGFRis had a higher risk of keratitis than nonexposed patients (hazard ratio [HR], 1.520; 95% CI, 1.339-1.725). Subtypes of EGFRi-associated keratitis included keratoconjunctivitis (HR, 1.367; 95% CI, 1.158-1.615), superficial keratitis (HR, 1.635; 95% CI, 1.306-2.047), and corneal ulcer (HR, 2.132; 95% CI, 1.515-3.002). Patients taking afatinib had a higher risk of keratitis (HR, 2.229; 95% CI, 1.480-3.356). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with lung cancer treated with EGFRis may have an increased risk of new-onset keratitis, especially with the second-generation EGFRi afatinib, supporting the need for prompt diagnosis and management of EGFRi-associated ocular issues to prevent serious complications or treatment disruptions.
引用
- Huang PC, Lin CC, Dana R, et al. Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis. JAMA Ophthalmol. 2024. PMID: 38206621. doi:10.1001/jamaophthalmol.2023.6089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。